Literature DB >> 10094199

Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies.

L Alvarez-Vallina1, S J Russell.   

Abstract

Engineered T cells expressing chimeric T cell receptors (chTCRs) are of interest for cancer gene therapy but many "cancer antigens" are thought to be unsuitable targets because they are expressed at low levels on normal tissues. We therefore sought to determine whether engineered T cells expressing variable surface densities of a high-affinity chTCR could discriminate different concentrations of the targeted antigen. We plotted the relationship between chTCR density and the concentration of target antigen using Jurkat T cells expressing a hapten-binding chTCR whose expression could be modulated by tetracycline. Our analysis reveals that there is a dynamic equilibrium between cell surface density of the chTCR and the antigen density that optimally triggers T cell activation. At a fixed density of target antigen, optimal T cell activation can be achieved only within a certain range of chTCR densities, while excessive TCR signaling triggers apoptosis of the engineered T cells. Our results show that T cells can be engineered to discriminate different antigen densities and that the T cell response to a fixed concentration of antigen can be optimized by tuning the cell surface density of TCRs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094199     DOI: 10.1089/10430349950018634

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Xiaojun Qian; Ajay K Gopal; David G Maloney; Catherine G Lindgren; Yukang Lin; John M Pagel; Lihua E Budde; Andrew Raubitschek; Stephen J Forman; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

2.  Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Lihua E Budde; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

3.  T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors.

Authors:  Eric Krawczyk; Sergey N Zolov; Kevin Huang; Challice L Bonifant
Journal:  Cancer Immunol Res       Date:  2019-02-19       Impact factor: 11.151

Review 4.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

5.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Authors:  Gregory A Rufener; Oliver W Press; Philip Olsen; Sang Yun Lee; Michael C Jensen; Ajay K Gopal; Barbara Pender; Lihua E Budde; Jeffrey K Rossow; Damian J Green; David G Maloney; Stanley R Riddell; Brian G Till
Journal:  Cancer Immunol Res       Date:  2016-04-21       Impact factor: 11.151

Review 6.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

7.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Authors:  Alec J Walker; Robbie G Majzner; Ling Zhang; Kelsey Wanhainen; Adrienne H Long; Sang M Nguyen; Paola Lopomo; Marc Vigny; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Mol Ther       Date:  2017-07-01       Impact factor: 11.454

Review 8.  Treatment of lymphoma with adoptively transferred T cells.

Authors:  Brian G Till; Oliver W Press
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

9.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

10.  A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Authors:  Jennifer D Stone; David H Aggen; Andrea Schietinger; Hans Schreiber; David M Kranz
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.